Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine
kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-…

The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents
a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …

Background The effects of extra-pleural pneumonectomy (EPP) on survival and quality of
life in patients with malignant pleural mesothelioma have, to our knowledge, not been …

Purpose: PTK787/ZK 222584 (PTK/ZK), an orally active inhibitor of vascular endothelial
growth factor (VEGF) receptor tyrosine kinases, inhibits VEGF-mediated angiogenesis. The …

Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …

Purpose The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with
afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling …

Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small-cell
lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …

Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved
progression-free survival (PFS), time-to-treatment failure (TTF) and objective response …

Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …